Pharmaron Beijing (HKG:3759, SHE:300759) expects to record net profit attributable to owners of parent between 1.73 billion yuan and 1.86 billion yuan for 2024, 8% to 16% higher than 1.60 billion yuan logged for the preceding year, a Tuesday Hong Kong bourse filing said.
The company expects its revenue to come between 12.0 billion yuan and 12.3 billion yuan for the reporting year, 4% to 7% higher than 11.5 billion yuan recorded a year ago.
Basic earnings per share are estimated to be between 0.98 yuan and 1.05 yuan, compared with 0.90 yuan per share booked for 2023.
The pharmaceutical company attributed the expected increase in its financial results for 2024 to an increase in its revenue and the non-recurring gains or losses during the period.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.